US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

The US FDA has approved Regenerons Libtayo, an immunotherapy, as an adjuvant treatment for high-risk skin cancer patients post-surgery and radiation, marking a significant advancement in cancer care.

On October 8, the Food and Drug Administration approved Regeneron Pharmaceuticals Libtayo, a treatment option for patients with skin cancer at high risk of recurrence after surgery and radiation.
Libtayo, also known as Cemiplimab, is designed to be used as an add-on therapy for individuals suffering from squamous cell carcinoma, a common type of skin cancer.
This decision expands the usage of Libtayo, providing a new treatment avenue for patients who are particularly vulnerable to their skin cancer returning following initial interventions.

Why It Matters

The FDAs approval of Libtayo as an adjuvant treatment signifies an important step in enhancing recovery options for skin cancer patients, reflecting the growing focus on personalized cancer therapies and improving long-term survival rates.